Antibody-drug conjugates payloads: then, now and next

Antibody-drug conjugates (ADCs) have been a revolutionary new approach for cancer treatments, with their ability to deliver cytotoxic drugs directly to diseased cells while leaving healthy tissues unharmed. This direct delivery reduces the harmful side effects commonly associated with traditional chemotherapy while allowing enhanced therapeutic efficacy.

In a recent article with Drug Target Review,  authors Dr Nicolas Camper, Dr Campbell Bunce and Dr Johanna Midelet from Abzena, reflect on how ADCs and their payloads have evolved, investigate the potential of dual-drug ADCs, and shine a spotlight on some of the less common payloads being explored for cancer treatments today.